Literature DB >> 14755317

Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.

E Kusumi1, M Kami, K Yuji, T Hamaki, N Murashige, A Hori, R Kojima, Y Kishi, S-W Kim, J Ueyama, S Miyakoshi, R Tanosaki, S Morinaga, S Mori, Y Heike, Y Muto, S Masuo, S Taniguchi, Y Takaue.   

Abstract

To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received RIST in the Tokyo SCT consortium from January 2000 to October 2002. The preparative regimens were fludarabine-based (150-180 mg/m(2), n=18) or cladribine-based (0.77 mg/kg, n=2). To enhance engraftment, antithymocyte globulin (ATG) and 4 or 8 Gy total body irradiation (TBI) were added to these regimens in nine and 11 patients, respectively. GVHD prophylaxis was cyclosporine with or without methotrexate. In all, 19 achieved primary engraftment. Three developed graft failure (one primary, two secondary), and five died of treatment-related mortality within 100 days of transplant. Seven of the 19 patients who achieved initial engraftment developed grade II-IV acute GVHD, and seven of 13 patients who survived >100 days developed chronic GVHD. At a median follow-up of 5.5 months, estimated 1-year overall survival was 35%. Compared with a TBI-containing regimen, an ATG-containing regimen was associated with a high risk of graft failure (30 vs 0%, P=0.0737). This study supports the feasibility of RIST from MUD; however, procedure-related toxicities remain significant in its application to patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755317     DOI: 10.1038/sj.bmt.1704425

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.

Authors:  Yoshihiro Inamoto; Taku Oba; Koichi Miyamura; Seitaro Terakura; Akane Tsujimura; Yachiyo Kuwatsuka; Masahiro Tokunaga; Masanobu Kasai; Makoto Murata; Tomoki Naoe; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.

Authors:  Yuji Miura; Takayuki Azuma; Eiji Kusumi; Tomoko Matsumura; Masahiro Kami; Tsunehiko Komatsu
Journal:  Int J Hematol       Date:  2007-12       Impact factor: 2.490

3.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

4.  Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.

Authors:  Takahiko Nakane; Hirohisa Nakamae; Hideo Koh; Mika Nakamae; Yoshiki Hayashi; Mitsutaka Nishimoto; Takuro Yoshimura; Eri Inoue; Atsushi Inoue; Ran Aimoto; Mizuki Aimoto; Yoshiki Terada; Ki-Ryang Koh; Takahisa Yamane; Masayuki Hino
Journal:  Int J Hematol       Date:  2011-03-12       Impact factor: 2.490

5.  Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.

Authors:  Sung-Won Kim; Keitaro Matsuo; Takahiro Fukuda; Masamichi Hara; Kosei Matsue; Shuichi Taniguchi; Tetsuya Eto; Mitsune Tanimoto; Atsushi Wake; Kazuo Hatanaka; Shinji Nakao; Yoji Ishida; Mine Harada; Atae Utsunomiya; Masahiro Imamura; Yoshinobu Kanda; Kazutaka Sunami; Fumio Kawano; Yoichi Takaue; Takanori Teshima
Journal:  Int J Hematol       Date:  2008-09-17       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.